stockrowTrulieve Cannabis Corp.
TRLV Healthcare Drug Manufacturers Specialty & Generic
Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- −20.1%
- EPS
- −2,391.1%
- Free cash flow
- +24.5%
- Total debt
- −37.0%
Quarter to September 2026, against a year earlier
Follow TRLV
Alert me
Trulieve Cannabis Corp. (TRLV) Return on equity
Trulieve Cannabis Corp.'s return on equity over the twelve months to 30 September 2026 was −45.5%, down 35.8 percentage points from fiscal 2025 (−9.73%). Over the past ten years it has ranged from −31.6% (fiscal 2023) to 0.00% (fiscal 2021); the current reading is higher than 67% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of −0.80% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −9.73% | 1.94 |
| FY2024 | −11.7% | 19.91 |
| FY2023 | −31.6% | (19.50) |
| FY2022 | −12.1% | (12.08) |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| BCRX BioCryst Pharmaceuticals, Inc. compare | 91.6% |
| ANIP ANI Pharmaceuticals, Inc. compare | 20.5% |
| PBH Prestige Consumer Healthcare Inc. compare | 8.23% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited compare | 0.00% |
| ALVO Alvotech compare | 0.00% |
| XERS Xeris Biopharma Holdings, Inc. compare | −27.1% |
| TRLV Trulieve Cannabis Corp. | −45.5% |
| PRGO Perrigo Company plc compare | −51.4% |
| Drug Manufacturers Specialty & Generic industry median | −0.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on TRLV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement